Vera Therapeutics (VERA) Gains from Investment Securities (2020 - 2026)
Vera Therapeutics posted quarterly Gains from Investment Securities of $4.4 million for Q1 2026, up 4274.32% year-on-year from $100587.0 in Q1 2025, and down 46.34% on a QoQ basis from $8.2 million in Q4 2025.
Vera Therapeutics (VERA) has 7 years of Gains from Investment Securities data on file, last reported at $4.4 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 4274.32% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 13520.05% YoY), and the FY2025 full-year result was $8.4 million, up 26.97% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4.4 million, down from $8.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $12.1 million in Q4 2024 and bottomed at $12641.0 in Q2 2022.
- The 5-year median for Gains from Investment Securities is $708897.0 (2024), against an average of $2.7 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities soared 23550.16%; it then slumped 97.14% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $2.3 million in 2022, then sank by 91.3% to $200000.0 in 2023, then soared by 5950.0% to $12.1 million in 2024, then slumped by 32.23% to $8.2 million in 2025, then plunged by 46.34% to $4.4 million in 2026.
- The last three Gains from Investment Securities figures came in at $4.4 million (Q1 2026), $8.2 million (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Mn |
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 8.20 Mn |
| Dec 31, 2025 | 8.20 Mn |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 100,587.00 |
| Mar 31, 2025 | 100,587.00 |
| Dec 31, 2024 | 12.10 Mn |
| Dec 31, 2024 | 12.10 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 10.60 Mn |
| Jun 30, 2024 | 10.60 Mn |
| Mar 31, 2024 | 708,897.00 |
| Mar 31, 2024 | 708,897.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 45,078.00 |
| Sep 30, 2023 | 45,078.00 |
| Jun 30, 2023 | 44,820.00 |
| Jun 30, 2023 | 44,820.00 |
| Mar 31, 2023 | 3.00 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 200,571.00 |
| Sep 30, 2022 | 200,571.00 |
| Jun 30, 2022 | 12,641.00 |
| Jun 30, 2022 | 12,641.00 |
| Mar 31, 2022 | 17,946.00 |
| Mar 31, 2022 | 17,946.00 |
| Dec 31, 2021 | 15.96 Mn |
| Dec 31, 2021 | 15.96 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 32,122.00 |
| Jun 30, 2021 | 32,122.00 |
| Mar 31, 2021 | 113,683.00 |
| Mar 31, 2021 | 113,683.00 |
| Dec 31, 2020 | 18,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Jun 30, 2020 | 1,382.00 |
| Jun 30, 2020 | 1,382.00 |
| Mar 31, 2020 | 48,000.00 |
| Mar 31, 2020 | 48,000.00 |